MX2024004619A - Formulacion farmaceutica que comprende el anticuerpo monoclonal anti-ox40. - Google Patents

Formulacion farmaceutica que comprende el anticuerpo monoclonal anti-ox40.

Info

Publication number
MX2024004619A
MX2024004619A MX2024004619A MX2024004619A MX2024004619A MX 2024004619 A MX2024004619 A MX 2024004619A MX 2024004619 A MX2024004619 A MX 2024004619A MX 2024004619 A MX2024004619 A MX 2024004619A MX 2024004619 A MX2024004619 A MX 2024004619A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
monoclonal antibody
packaging
disclosed
monoclonal
Prior art date
Application number
MX2024004619A
Other languages
English (en)
Spanish (es)
Inventor
Qiang Sun
Xionghua Jin
Pengcheng Fan
Zhihao Xu
Original Assignee
Inmagene Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmagene Pte Ltd filed Critical Inmagene Pte Ltd
Publication of MX2024004619A publication Critical patent/MX2024004619A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2024004619A 2021-10-15 2022-10-13 Formulacion farmaceutica que comprende el anticuerpo monoclonal anti-ox40. MX2024004619A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021124200 2021-10-15
CN2022118065 2022-09-09
PCT/CN2022/125017 WO2023061424A1 (en) 2021-10-15 2022-10-13 Pharmaceutical formulation comprising anti-ox40 monoclonal antibody

Publications (1)

Publication Number Publication Date
MX2024004619A true MX2024004619A (es) 2024-07-12

Family

ID=85987310

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004619A MX2024004619A (es) 2021-10-15 2022-10-13 Formulacion farmaceutica que comprende el anticuerpo monoclonal anti-ox40.

Country Status (13)

Country Link
US (1) US20250282882A1 (cg-RX-API-DMAC7.html)
EP (1) EP4415754A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024538140A (cg-RX-API-DMAC7.html)
KR (1) KR20240109250A (cg-RX-API-DMAC7.html)
CN (1) CN118541166A (cg-RX-API-DMAC7.html)
AU (1) AU2022367611A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235879A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001157A1 (cg-RX-API-DMAC7.html)
IL (1) IL312138A (cg-RX-API-DMAC7.html)
MX (1) MX2024004619A (cg-RX-API-DMAC7.html)
PE (1) PE20241351A1 (cg-RX-API-DMAC7.html)
TW (1) TW202323280A (cg-RX-API-DMAC7.html)
WO (1) WO2023061424A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4136116A4 (en) * 2020-04-17 2024-06-19 Hutchison Medipharma Limited ANTI-OX40 ANTIBODIES AND USES THEREOF
CN117257936B (zh) * 2023-10-30 2026-05-01 杭州博之锐生物制药有限公司 一种阿达木单抗组合物
WO2025185555A1 (en) * 2024-03-04 2025-09-12 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Pharmaceutical compositions comprising ox40 targeting antibodies and uses thereof
WO2026130530A1 (en) * 2024-12-19 2026-06-25 Akeso Biopharma Co., Ltd. Antibody formulations with reduced aggregation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100014588A (ko) * 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ox40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
SG11201607969XA (en) * 2014-03-31 2016-10-28 Genentech Inc Anti-ox40 antibodies and methods of use
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
ES3014697T3 (en) * 2018-07-19 2025-04-24 Ichnos Sciences S A Liquid antibody formulation
TWI726426B (zh) * 2018-09-25 2021-05-01 大陸商信達生物製藥(蘇州)有限公司 包含抗ox40抗體的製劑、其製備方法及其用途
EP3999537A1 (en) * 2019-07-19 2022-05-25 Ichnos Sciences SA Lyophilized antibody formulation
TW202144005A (zh) * 2020-03-25 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 一種抗ox40抗體醫藥組成物及其用途

Also Published As

Publication number Publication date
CN118541166A (zh) 2024-08-23
WO2023061424A1 (en) 2023-04-20
CL2024001157A1 (es) 2024-11-15
KR20240109250A (ko) 2024-07-10
TW202323280A (zh) 2023-06-16
EP4415754A4 (en) 2025-09-24
US20250282882A1 (en) 2025-09-11
JP2024538140A (ja) 2024-10-18
CA3235879A1 (en) 2023-04-20
PE20241351A1 (es) 2024-07-03
AU2022367611A1 (en) 2024-05-02
IL312138A (en) 2024-06-01
EP4415754A1 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
CL2024001157A1 (es) Formulación farmacéutica que comprende el anticuerpo monoclonal anti-ox40
PH12019502123A1 (en) Stable antibody formulation
ZA202205141B (en) Formulations of human anti-rankl antibodies, and methods of using the same
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
BR112021026414A2 (pt) Formulação compreendendo o anticorpo biespecífico anti-cd47/pd-l1, método para preparo e uso do mesmo
BR112017008660A2 (pt) formulação de solução de proteína estável contendo alta concentração de um anticorpo anti-vegf
PH12021552788A1 (en) Stabilized formulations containing anti-angptl3 antibodies
BR112018005349A2 (pt) preparação farmacêutica de anticorpo anti-pd-1 estável e sua aplicação em medicamentos
EA201991299A1 (ru) Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов
AR095396A1 (es) Formulaciones de anticuerpo
MX2016015006A (es) Formulacion de anticuerpos.
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
JOP20210152A1 (ar) صياغة محلول بروتيني محتوية على تركيز عالٍ من جسم مضاد لـ vegf
NZ735820A (en) Compositions comprising a combination of an anti-pd-1 antibody and another antibody
PH12021551916A1 (en) Therapeutic antibody formulation.
CN110494164A (zh) 一种靶向治疗TNF-α相关疾病的人抗体制剂
CR20210480A (es) Formulaciones farmacéuticas
FI3528787T3 (fi) Farmaseuttisia formulaatioita ja menetelmiä niiden valmistamiseksi
SA521430229B1 (ar) Il-33 صيغ ثابتة تحتوي على أجسام مضادة لـ
BR112022001775A2 (pt) Formulação compreendendo o anticorpo biespecífico anti-pd-1/her2, método para preparo e uso do mesmo
MX2022016403A (es) Formulaciones de anticuerpo de activina a y métodos para utilizarlas.
AR130115A2 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
MX2025010272A (es) Formulaciones de anticuerpos anti-fel d1
EA201800360A1 (ru) Способ получения фармацевтической композиции, содержащей бендамустин, фармацевтическая композиция бендамустина